The average of price targets set by Wall Street analysts indicates a potential upside of 37% in Deluxe (DLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

XCel Brands (XELB) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.1 per share a year ago.

Newmark Group, Inc. (NMRK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, NMRK's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The consensus price target hints at an 187.7% upside potential for Bicara Therapeutics Inc. (BCAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The mean of analysts' price targets for The Beachbody Company (BODI) points to an 114.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

I rate SKYY a hold due to its strong cloud/A.I. growth prospects but high valuations make me cautious about buying now. SKYY is well-positioned with large-cap cloud leaders and benefits from digital transformation, but its top holdings concentration adds risk. The fund outperforms peers and should deliver double-digit growth, but high multiples mean volatility and sensitivity to interest rates.

Apple announced a redesigned blood oxygen feature is rolling out to some Apple Watch users. The company has been embroiled in a years-long intellectual property dispute with Masimo over the capability.

Edible Garden AG Incorporated (NASDAQ:EDBL ) Q2 2025 Earnings Conference Call August 14, 2025 8:00 AM ET Company Participants James E. Kras - Founder, CEO, President, Treasurer, Secretary & Chairman Kostas Dafoulas - Interim Chief Financial Officer Conference Call Participants Anthony V.

Key Points in This Article: July's CPI signaled cooling inflation, boosting expectations for Fed rate cuts in September, but a bigger-than-expected increase in the PPI tempered enthusiasm slightly.

Markets hit fresh highs on low inflation???Zacks flags ANET, TEL, MSI, BBVA, and APP as high-ROE picks poised for strong returns.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novo Nordisk's current valuation is highly attractive, offering a compelling risk-reward for turnaround investors despite recent stock declines and margin pressures. GLP-1 therapies, especially Ozempic and Wegovy, are driving robust growth, but competition from Eli Lilly and compounded versions present near-term headwinds. Strong fundamentals include industry-leading margins, high ROE, consistent share buybacks, and a fast-growing dividend yield, supporting long-term shareholder value.